Little over year after IPO, biotech’s majority owner wants to buy it all For more information please click here to contact Tuan Nguyen By Bizjournals.com Feed (2019-07-12 16:19:27) | August 12, 2019 BridgeBio already owns two-thirds of Eidos, the rare disease spinout from Stanford University labs. Posted in Sacramento Business Journal